Cancer clinical trials | Salem Health Cancer Institute | Salem, OR
If you are experiencing flu-like or COVID-19 symptoms, call us at 503-814-0099 before visiting any of our locations. Learn more.

Cancer clinical trials

Comparing accepted cancer treatments with new types of treatments

We are proud to offer patients innovative treatment options through clinical research trials. Our affiliation with the Knight Cancer Institute means that that we work closely with researchers to provide quality cancer care.

Our clinical trials are tailored to the needs of the community. We conduct phase II-IV drug trials as well as trials that include surgery and radiation therapy. We also offer quality-of-life trials.

We use the same ethical and professional guidelines as larger academic medical centers and often exceed those standards. We are subject to the same federal standards and oversight as nationally recognized institutions.

Nurse touching a senior man's shoulder


Talk with your doctor to see if clinical trials are an option for you. Or call our clinical research department at 503-814-1435.


Frequently asked questions about clinical trials

What is a clinical trial?
Why should I participate?
What are the risks of participation?
How do I know whether I can participate?
Will the treatment be free?
Are all the studies treatment studies?
Are all patients on chemotherapy studies treated in the hospital?
Can I drop out of the clinical trial?
What cancer clinical trials will Medicare pay for?
Are clinical trials monitored?

Expand all

Collapse all



Currently open cancer clinical trials

Protocol: Aurora Research ADX02C

Title: Procurement of human bio-specimens for the discovery and validation or biomarkers for the prediction, diagnosis and management of oncologic disease.

Treatment: No treatment. Tissue specimens are collected from remaining tissue obtained during standard treatment after all routine testing has been performed. Blood specimens are collected prior to routine surgery, and if possible collected during routine laboratory visits. If that is not possible, blood specimens are collected before surgery on the same day.


  1. Be at least 18 years of age or older.
  2. Be able to provide medical information relevant to the Collection Initiative in which they are participating.
  3. Be capable of voluntarily signing, or have a Legally Authorized Representative (LAR) sign the most current IRB/IEC approved Informed Consent and Authorization Form prior to participating.
  4. Meet any additional inclusion criteria specified in all Core and peripheral collection initiatives.
  5. Be able to provide the required bio-specimen types without compromising the current health status of the Subject OR alternatively have pre-existing bio-specimens suitable for inclusion in the Collection Initiative whereby additional collections are not necessary.


Protocol: Breast - A011202

Title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvent Chemotherapy.

Treatment: Patients will be randomized to two study groups if cancer-positive lymph nodes are identified during surgery or at final pathology. Patients will either have axillary lymph node dissection and radiation treatment combined, or only radiation treatment.


  1. Patients must be at least 18 years of age.
  2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy).
  3. No inflammatory breast cancer.
  4. No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix.
  5. No neoadjuvant endocrine therapy.
  6. No neoadjuvant radiation therapy.
    More eligibility criteria must be met.



Title: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Treatment: This is an observational study.


  1. Must be able to provide a written informed consent form (ICF).
  2. Newly diagnosed,* primary or secondary MDS or AML, or ICUS.
  3. Cohort assignment confirmed by Central Eligibility Review.
  4. AML patient must be at least 55 years of age at the time of ICF signature.
  5. MDS/ICUS patient must be at least 18 years of age at the time of ICF signature.
  6. Must be willing and able to complete enrollment and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish.


Protocol: CLL - EA9161

Title: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Treatment: Patients will be randomized to two study groups — either patients will be randomized to Arm A with Ibrutinib, obinutuzumab, venetoclax, or Arm B with Ibrutinib and obinutuzumab.


  1. Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria.
  2. No prior chemotherapy, BTK inhibitor therapy, venetoclax, small molecule signaling inhibitor, or monoclonal anti-body therapy for the treatment of CLL or SLL
  3. Age ≥ 18 years and < 70.
  4. ECOG performance status between 0-2.
  5. Life expectancy of ≥ 12 months.
    More eligibility criteria must be met.


Protocol: Lung-MAP – LungMap Screening

Title: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Treatment: After completing the screening, participants have the option to be assigned to a sub-study based off the biomarker findings.


  1. Patients must have pathologically proven non-small cell lung cancer (all histologic types) confirmed by tumor biopsy and/or fine-needle aspiration.
  2. Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on current treatment.
  3. Patients must not have a known EGFR mutation or ALK fusion.
  4. Patients must be ≥ 18 years of age.
  5. Patients must have adequate tumor tissue available, defined as ≥ 20% tumor cells and ≥ 0.2 mm3 tumor volume
    More eligibility criteria must be met.


Protocol: Get Fit Prostate

Description: Get Fit Prostate (Group Exercise Training for Fall prevention and functional Improvements during and after Treatment for Prostate cancer). The study is a 3-group, single-blind, parallel design randomized, controlled trial in prostate cancer survivors treated with ADT. Participants in each study group will attend supervised 1-hr classes, 3 days a week for 6 months.

ARM 1: Tai ji quan, an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements, specifically designed to challenge limits of stability and train gait patterns, as reflected in movements such as upright trunk positioning, displacement of body's center of mass over the weight-bearing leg, and step initiation, locomotion, and termination.

ARM 2: Strength training. Participants wear a weighted vest while performing exercises using functional movement patterns that challenge balance by using muscle groups and movement involved in everyday activities (chair rises, 90°squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step-ups).

ARM 3: Stretching control. Participants in the control group will attend a supervised flexibility program of the same total weekly duration as the experimental arms (e.g., 3, 60-min sessions per week). Control participants will perform a series of whole-body stretching exercises, according to the ACSM guidelines for flexibility training, with a focus on developing and maintaining a healthy back.

Six-month follow-up: Participants will be followed for an additional six months after the six-month supervised intervention stops to track falls (using the same monthly report used during the intervention phase). Exercise questionnaires to track participation in-home or community exercise programs and will be collected at the 9- and 12-month time periods.

Inclusion Criteria:

  • Diagnosed with histologically confirmed prostate cancer.
  • Currently on ADT for >= 6 months OR not currently receiving ADT, but received >= 6-month course within the last 10 years.
  • Completed any surgery, radiation or chemotherapy ≥ 6 weeks prior to enrollment and no concurrent adjuvant therapy other than ADT for prostate cancer
  • Meets criteria for having experienced ≥1 fall in the last year (confirmed by self-report on Health History Questionnaire) or if no falls, meets criteria for slow TUG time (≥12.0 seconds) OR slow chair stand time (≥10.0 seconds).

Exclusion Criteria:

  • Current participation in moderate-vigorous intensity lower-body strength training two or more times per week for 30 minutes or more or participating in tai chi two or more times per week for 30 minutes or more.
  • Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent.
  • A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate-intensity exercise.
  • Not medically cleared for participation in moderate-intensity exercise.

Additional information: